openPR Logo
Press release

Bronchiolitis Market is expected to reach USD 1.9 billion by 2034

09-03-2025 02:00 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Bronchiolitis

Bronchiolitis

Bronchiolitis is a common respiratory condition in infants and young children, characterized by inflammation of the small airways in the lungs, often caused by viral infections, most notably respiratory syncytial virus (RSV). The disease leads to difficulty breathing, wheezing, and coughing, and in severe cases, can result in hospitalization.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71469

Bronchiolitis typically affects children under two years old, and while the majority of cases are self-limiting, severe instances require pediatric care and hospitalization. With rising respiratory infections, particularly RSV, and a growing focus on pediatric healthcare, the bronchiolitis market is expected to expand significantly through 2034. Recent advancements in vaccine development, antiviral therapies, and supportive treatments are driving the market's growth.

Market Overview
• Market Size (2024): USD 1.1 billion
• Forecast (2034): USD 1.9 billion
• CAGR (2025-2034): ~7.5%
• Key Growth Drivers: Increasing incidence of respiratory infections, rising awareness of bronchiolitis management, and innovations in antiviral treatments.
• Key Challenges: High hospitalization rates, limited treatment options for severe cases, and inadequate awareness in certain regions.
• Leading Players: Abbott Laboratories, Sanofi, Pfizer, GSK, AstraZeneca, Merck & Co., Novartis, and Regeneron Pharmaceuticals.

Segmentation Analysis
By Therapy Type
• Antiviral Therapies (e.g., palivizumab, nebulized ribavirin)
• Bronchodilators (e.g., salbutamol)
• Corticosteroids
• Oxygen Therapy
• Supportive Care (e.g., fluid management, nasal suctioning, hydration)

By Route of Administration
• Oral
• Injectable (e.g., palivizumab)
• Inhaled (e.g., nebulized therapies)

By End Use
• Hospitals (pediatric care units, emergency departments)
• Specialized Pediatric Clinics
• Ambulatory Care Centers
• Homecare

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Summary: Antiviral therapies such as palivizumab are becoming increasingly important for managing severe cases, while supportive care and oxygen therapy remain the mainstay for mild to moderate cases.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71469/bronchiolitis-market

Regional Analysis
• North America: Largest market share, driven by high RSV infection rates, increasing healthcare access, and advancements in preventative care (e.g., palivizumab).
• Europe: Significant growth, especially in countries with advanced pediatric care infrastructure and high RSV prevalence rates (e.g., the UK, Germany, and France).
• Asia-Pacific: Fastest-growing region, driven by rising healthcare access, urbanization, and increasing respiratory disease prevalence in countries like China, India, and Japan.
• Middle East & Africa: Growing demand for bronchiolitis care, particularly in GCC countries investing in pediatric healthcare services.
• Latin America: Brazil and Mexico lead regional demand, supported by increasing access to antiviral therapies and pediatric care services.

Summary: North America and Europe dominate in terms of value, but Asia-Pacific is projected to post the highest CAGR (~8%) through 2034, reflecting improving healthcare access and increasing disease burden.

Market Dynamics
Key Growth Drivers
• Increased incidence of RSV and other respiratory infections, especially in children under two years of age.
• Advancements in antiviral therapies, such as monoclonal antibodies (e.g., palivizumab), for RSV prophylaxis.
• Rising awareness of bronchiolitis and improving diagnosis and management practices globally.
• Expanding access to pediatric healthcare, particularly in emerging markets, with more specialized pediatric units.

Key Challenges
• Limited treatment options for severe bronchiolitis beyond supportive care, leading to high hospitalization rates.
• High cost of antiviral therapies like palivizumab, limiting access, especially in low-income countries.
• Inadequate awareness and diagnostic capabilities in rural and underdeveloped regions.

Latest Trends
• Research into vaccine development for RSV and other respiratory viruses to reduce bronchiolitis incidence.
• Biologic therapies like palivizumab becoming standard in RSV prevention for high-risk infants.
• Homecare solutions for mild cases, allowing for more efficient management outside hospital settings.
• Growing digital health initiatives for remote monitoring and pediatric care in regions with healthcare access gaps.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71469

Competitor Analysis
Major Players
• Abbott Laboratories - Leader in pediatric healthcare and diagnostics, providing respiratory care solutions.
• Sanofi - Known for palivizumab, a key RSV monoclonal antibody for prevention of severe bronchiolitis.
• Pfizer - Innovating in respiratory infections treatments and developing RSV vaccines.
• GSK - Developing treatments for respiratory conditions, including bronchiolitis.
• AstraZeneca - Expanding bronchodilators and respiratory care products.
• Merck & Co. - Active in RSV research and vaccine development.
• Novartis - Focused on respiratory care and supporting pediatric asthma and bronchiolitis therapies.
• Regeneron Pharmaceuticals - Innovating in monoclonal antibodies and RSV treatments.

Summary: The bronchiolitis market is dominated by pharmaceutical giants like Sanofi, Pfizer, and Abbott, with significant contributions from GSK and AstraZeneca in respiratory care. Regeneron and Merck are also making strides in RSV vaccine and monoclonal antibody development.

Conclusion
The bronchiolitis market is poised for steady growth, driven by advancements in antiviral therapies, RSV prevention, and improving pediatric healthcare access. With a projected CAGR of ~7.5% (2025-2034), the market outlook is positive, though challenges related to high treatment costs and global healthcare disparities remain.
Key Takeaways:
• Antiviral therapies, particularly monoclonal antibodies like palivizumab, are key drivers of market growth.
• Asia-Pacific will see the highest growth, reflecting increased healthcare access and rising disease burden.
• Homecare solutions and digital health tools are helping manage mild cases more effectively.
• Companies that focus on preventative treatments, RSV vaccines, and affordable therapies will lead the market.
The next decade promises better prevention, treatment, and care options, making the bronchiolitis market one of the most important segments in pediatric respiratory care.

This report is also available in the following languages : Japanese (細気管支炎市場), Korean (세기관지염 시장), Chinese (细支气管炎市场), French (Marché de la bronchiolite), German (Bronchiolitis-Markt), and Italian (Mercato della bronchiolite), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71469/bronchiolitis-market#request-a-sample

Our More Reports:

Erythema Market
https://exactitudeconsultancy.com/reports/71411/erythema-market

Dyschromia Market
https://exactitudeconsultancy.com/reports/71409/dyschromia-market

Diffuse cutaneous systemic sclerosis Market
https://exactitudeconsultancy.com/reports/71407/diffuse-cutaneous-systemic-sclerosis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bronchiolitis Market is expected to reach USD 1.9 billion by 2034 here

News-ID: 4168490 • Views:

More Releases from Exactitude Consultancy

Asthma Market Projected to Reach USD 38 Billion by 2034
Asthma Market Projected to Reach USD 38 Billion by 2034
Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty in breathing, wheezing, and coughing. It affects millions of people worldwide and has a significant impact on quality of life, work productivity, and healthcare costs. While asthma can be controlled with bronchodilators, corticosteroids, and inhalers, treatment adherence and asthma control remain a challenge for many patients. Download Full PDF Sample Copy of Market Report
Acute Respiratory Distress Syndrome Market to Double, Reach USD 13 Billion by 2034
Acute Respiratory Distress Syndrome Market to Double, Reach USD 13 Billion by 20 …
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by widespread inflammation in the lungs, leading to severe respiratory failure. It is commonly associated with other underlying conditions, such as pneumonia, trauma, sepsis, and aspiration, causing difficulty in oxygen exchange. Despite advancements in mechanical ventilation and supportive care, ARDS remains a major cause of morbidity and mortality, especially in critically ill patients. Download Full PDF Sample Copy of Market Report
MAC Lung Disease Market Growth, Trends, Consumer Demand and Key Opportunities
MAC Lung Disease Market Growth, Trends, Consumer Demand and Key Opportunities
Introduction Mycobacterium avium complex (MAC) lung disease is a chronic infection caused by a group of bacteria within the Mycobacterium avium species. It primarily affects individuals with pre-existing lung conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis. MAC lung disease is also becoming increasingly recognized in immunocompromised populations, including those with HIV/AIDS. The disease can lead to persistent cough, fatigue, weight loss, and difficulty breathing, and it
Seasonal Allergic Rhinitis Market 2025-2034 Business Outlook, Critical Insight and Growth
Seasonal Allergic Rhinitis Market 2025-2034 Business Outlook, Critical Insight a …
Introduction Seasonal allergic rhinitis (SAR), commonly known as hay fever, is an allergic reaction that occurs during specific seasons, typically triggered by pollen from trees, grasses, and weeds. SAR causes symptoms such as sneezing, nasal congestion, itchy eyes, and runny nose, significantly impacting quality of life. With rising levels of airborne allergens due to climate change, the incidence of seasonal allergic rhinitis is on the rise worldwide. The Seasonal Allergic Rhinitis Market

All 5 Releases


More Releases for RSV

The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025? The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025,
RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on …
According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period. To request quote of this report, please visit: https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html In the dynamic landscape of preventive therapies for respiratory
RSV Diagnostics Market to Signify Strong Growth by 2024-2031
The RSV (Respiratory Syncytial Virus) Diagnostics market is experiencing significant growth due to the increasing prevalence of RSV infections, advancements in diagnostic technologies, and the rising demand for accurate and rapid diagnostic solutions. RSV is a common respiratory virus that causes infections in the lungs and respiratory tract, particularly affecting infants, young children, and the elderly. Market Overview The global RSV Diagnostics market is projected to witness substantial growth over the coming
Global RSV Diagnostic Products Market Size & Trends
According to a new market research report published by Global Market Estimates, the global RSV diagnostic products market is expected to grow at a CAGR of 11.4% from 2023 to 2028. Ongoing advancements in diagnostic technologies, specifically PCR and rapid point-of-care testing, play a crucial role. These advancements offer heightened accuracy, faster results, and increased accessibility, enabling prompt and precise identification of RSV infections. Browse 147 Market Data Tables and 115 Figures
Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Reach USD 9080.84 …
Respiratory Syncytial Virus (RSV) Therapeutics Market Scope & Overview Respiratory Syncytial Virus (RSV) Therapeutics Market size was USD 1040.65 Million in 2022 and is expected to Reach USD 9080.84 Million by 2030 and grow at a CAGR of 31.1% over the forecast period of 2023-2030. The Respiratory Syncytial Virus (RSV) Therapeutics market is a vibrant, fiercely competitive sector that is essential to digital marketing. The demand for effective has increased as companies
Respiratory Syncytial Virus (RSV) Therapeutics Market - Conquering RSV: Advancin …
Newark, New Castle, USA: The "Respiratory Syncytial Virus (RSV) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519 This latest report